United Therapeutics Co. (NASDAQ:UTHR) Shares Acquired by Atika Capital Management LLC

Atika Capital Management LLC raised its position in United Therapeutics Co. (NASDAQ:UTHR - Free Report) by 12.7% during the fourth quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 31,000 shares of the biotechnology company's stock after purchasing an additional 3,500 shares during the quarter. United Therapeutics accounts for approximately 1.2% of Atika Capital Management LLC's portfolio, making the stock its 23rd largest position. Atika Capital Management LLC owned about 0.07% of United Therapeutics worth $10,938,000 at the end of the most recent reporting period.

A number of other large investors also recently added to or reduced their stakes in the company. Russell Investments Group Ltd. boosted its holdings in United Therapeutics by 35.1% during the 4th quarter. Russell Investments Group Ltd. now owns 88,077 shares of the biotechnology company's stock valued at $31,077,000 after acquiring an additional 22,895 shares during the period. Envestnet Asset Management Inc. grew its holdings in shares of United Therapeutics by 5.0% in the fourth quarter. Envestnet Asset Management Inc. now owns 60,880 shares of the biotechnology company's stock valued at $21,481,000 after purchasing an additional 2,889 shares in the last quarter. Grantham Mayo Van Otterloo & Co. LLC lifted its holdings in United Therapeutics by 101.2% during the 4th quarter. Grantham Mayo Van Otterloo & Co. LLC now owns 8,227 shares of the biotechnology company's stock worth $2,903,000 after buying an additional 4,139 shares in the last quarter. Resona Asset Management Co. Ltd. purchased a new position in United Therapeutics in the 4th quarter valued at approximately $6,902,000. Finally, Integrated Quantitative Investments LLC acquired a new position in shares of United Therapeutics in the fourth quarter worth $392,000. 94.08% of the stock is currently owned by institutional investors and hedge funds.

Remove Ads

United Therapeutics Stock Up 1.2 %

UTHR traded up $3.35 during trading on Friday, hitting $282.24. 115,132 shares of the stock were exchanged, compared to its average volume of 460,086. United Therapeutics Co. has a 1-year low of $230.39 and a 1-year high of $417.82. The stock has a fifty day moving average price of $324.67 and a two-hundred day moving average price of $351.68. The firm has a market capitalization of $12.68 billion, a P/E ratio of 12.40, a PEG ratio of 0.97 and a beta of 0.63.

United Therapeutics (NASDAQ:UTHR - Get Free Report) last released its quarterly earnings results on Wednesday, February 26th. The biotechnology company reported $6.19 EPS for the quarter, beating the consensus estimate of $6.10 by $0.09. The firm had revenue of $735.90 million during the quarter, compared to the consensus estimate of $734.74 million. United Therapeutics had a net margin of 40.31% and a return on equity of 19.22%. During the same quarter in the prior year, the firm earned $4.36 EPS. Analysts predict that United Therapeutics Co. will post 24.48 EPS for the current year.

Insider Buying and Selling at United Therapeutics

In other news, EVP Paul A. Mahon sold 11,000 shares of United Therapeutics stock in a transaction dated Thursday, April 3rd. The shares were sold at an average price of $306.18, for a total value of $3,367,980.00. Following the sale, the executive vice president now owns 36,781 shares of the company's stock, valued at $11,261,606.58. The trade was a 23.02 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, Director Raymond Dwek sold 4,000 shares of the firm's stock in a transaction dated Monday, April 7th. The shares were sold at an average price of $284.55, for a total transaction of $1,138,200.00. Following the completion of the sale, the director now owns 1,750 shares of the company's stock, valued at approximately $497,962.50. The trade was a 69.57 % decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 87,500 shares of company stock valued at $30,640,680 in the last ninety days. Insiders own 11.90% of the company's stock.

Wall Street Analyst Weigh In

A number of research analysts recently issued reports on the company. UBS Group lifted their target price on United Therapeutics from $415.00 to $475.00 and gave the company a "buy" rating in a report on Wednesday, January 8th. StockNews.com cut shares of United Therapeutics from a "strong-buy" rating to a "buy" rating in a report on Thursday, February 27th. Finally, HC Wainwright reiterated a "buy" rating and set a $425.00 price target on shares of United Therapeutics in a report on Thursday, February 27th. One investment analyst has rated the stock with a sell rating, two have assigned a hold rating and ten have issued a buy rating to the stock. According to MarketBeat, United Therapeutics currently has an average rating of "Moderate Buy" and a consensus target price of $388.25.

United Therapeutics Profile

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients.